Accenture Rebounds After Friday Selloff as Anthropic Partnership Draws Attention

Accenture PLC (NYSE:ACN) shares rose in Monday premarket trading as investors reacted to a new partnership with Anthropic focused on AI safety and model evaluation.

The rebound followed a 4.7% decline Friday, when Guggenheim downgraded Accenture to Neutral amid concerns about consulting demand.

Accenture, Anthropic Plan At Least $1 Billion Each For AI Safety

Accenture and Anthropic announced Friday that each expects to invest at least $1 billion over the next five years in AI safety.

The companies will establish a team of "embedded evaluators" to work alongside Anthropic’s internal teams and safety partners.

The team will evaluate and red-team AI models, conduct alignment assessments and test safeguards as organizations deploy AI systems.

Faculty Brings AI Testing Expertise

Accenture will draw on expertise from Faculty, the applied AI company it acquired.

Faculty has tested models for leading AI labs and developed AI systems across government, defense, healthcare and infrastructure. It also developed the U.K. National Health Service’s Early Warning System during the COVID-19 pandemic.

Accenture Chair and CEO Julie Sweet said, "Safety requires both deep technical expertise and a clear understanding of how AI is used in the real world."

Dr. Marc Warner, Accenture chief technology officer and Faculty CEO, said the partnership will allow Faculty to pursue embedded evaluation "at a scale that can genuinely move the industry."

ACN Eyes 200-Day Average

At $195.88, Accenture shares were above the 20-day SMA of $186.44 and the 50-day SMA of $170.99, but remained below the 200-day SMA of $200.12.

The 200-day average is now the key technical level to watch. A sustained move above it could signal a stronger improvement in the longer-term trend.

Momentum remains neutral, with RSI at 49.55. The 20-day SMA is above the 50-day average, supporting the recent recovery, while the 50-day SMA remains below the 200-day average.

Support sits near $175.50, close to the 50-day EMA of $176.44.

ACN is down 24.46% over the past 12 months.

Earnings And Wall Street Expectations

Accenture is scheduled to report earnings on Oct. 1, 2026.

Wall Street expects earnings of $3.18 per share, up from $3.03 a year earlier. Revenue is estimated at $18.03 billion, compared with $17.60 billion a year ago.

Accenture carries a Buy consensus rating with an average price target of $194.60.

Recent analyst actions highlight the debate around Accenture’s growth outlook.

Deutsche Bank maintained Hold while raising its price target to $175 on Sept. 18. Guggenheim downgraded the stock to Neutral the same day, while Morgan Stanley maintained Equal-Weight and raised its target to $175 on Sept. 14.

ACN Stock Price Activity: Accenture shares were up 6.38% at $192.86 during premarket trading on Monday, according to Benzinga Pro data.

Image via Shutterstock